Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinoblastoma | 3 | 2014 | 318 | 0.860 |
Why?
|
| Neoplasms, Second Primary | 2 | 2014 | 1061 | 0.530 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2021 | 501 | 0.520 |
Why?
|
| Medulloblastoma | 4 | 2015 | 683 | 0.510 |
Why?
|
| Retinal Neoplasms | 2 | 2014 | 144 | 0.510 |
Why?
|
| Germinoma | 3 | 2021 | 133 | 0.510 |
Why?
|
| Cerebellar Neoplasms | 3 | 2015 | 587 | 0.500 |
Why?
|
| Linear Energy Transfer | 2 | 2015 | 154 | 0.470 |
Why?
|
| Paraganglioma | 1 | 2013 | 143 | 0.400 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 441 | 0.350 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2013 | 298 | 0.350 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 547 | 0.340 |
Why?
|
| Hemangioma | 1 | 2013 | 738 | 0.320 |
Why?
|
| SEER Program | 1 | 2013 | 1508 | 0.310 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 760 | 0.290 |
Why?
|
| Hippocampus | 1 | 2019 | 3675 | 0.290 |
Why?
|
| Glioma | 1 | 2019 | 3401 | 0.240 |
Why?
|
| Lymphoma | 1 | 2013 | 1877 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 2734 | 0.210 |
Why?
|
| Brain Neoplasms | 5 | 2021 | 8863 | 0.210 |
Why?
|
| Carcinoma | 1 | 2013 | 2375 | 0.200 |
Why?
|
| Free Tissue Flaps | 2 | 2015 | 328 | 0.190 |
Why?
|
| Otolaryngology | 3 | 2019 | 645 | 0.150 |
Why?
|
| Patient Advocacy | 1 | 2019 | 353 | 0.150 |
Why?
|
| Larynx, Artificial | 1 | 2017 | 69 | 0.150 |
Why?
|
| Laryngectomy | 2 | 2017 | 248 | 0.140 |
Why?
|
| Relative Biological Effectiveness | 2 | 2015 | 323 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2015 | 895 | 0.130 |
Why?
|
| Auditory Brain Stem Implants | 1 | 2015 | 30 | 0.130 |
Why?
|
| Speech, Alaryngeal | 1 | 2015 | 32 | 0.130 |
Why?
|
| Pharyngectomy | 1 | 2015 | 45 | 0.130 |
Why?
|
| Cervicoplasty | 1 | 2015 | 8 | 0.130 |
Why?
|
| Cranial Irradiation | 2 | 2015 | 401 | 0.130 |
Why?
|
| Supratentorial Neoplasms | 2 | 2013 | 160 | 0.130 |
Why?
|
| Conflict of Interest | 1 | 2019 | 544 | 0.120 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2013 | 43 | 0.110 |
Why?
|
| Voice Quality | 1 | 2015 | 217 | 0.110 |
Why?
|
| Adolescent | 10 | 2021 | 85781 | 0.110 |
Why?
|
| Child, Preschool | 9 | 2021 | 41006 | 0.110 |
Why?
|
| Drug Industry | 1 | 2019 | 746 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 604 | 0.110 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 642 | 0.110 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2013 | 140 | 0.110 |
Why?
|
| Monte Carlo Method | 2 | 2015 | 1254 | 0.100 |
Why?
|
| Pineal Gland | 1 | 2013 | 166 | 0.100 |
Why?
|
| Neurofibromatosis 2 | 1 | 2015 | 380 | 0.100 |
Why?
|
| Travel | 1 | 2017 | 788 | 0.100 |
Why?
|
| Child | 9 | 2021 | 77709 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 413 | 0.100 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2014 | 312 | 0.100 |
Why?
|
| Deafness | 1 | 2015 | 458 | 0.100 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 212 | 0.100 |
Why?
|
| Speech Perception | 1 | 2015 | 489 | 0.090 |
Why?
|
| Ependymoma | 1 | 2013 | 334 | 0.090 |
Why?
|
| Brain Stem | 1 | 2015 | 846 | 0.090 |
Why?
|
| Teratoma | 1 | 2013 | 395 | 0.090 |
Why?
|
| Memory | 1 | 2019 | 2174 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 1 | 2013 | 548 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2015 | 555 | 0.090 |
Why?
|
| Survivors | 1 | 2019 | 2291 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2015 | 1301 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2017 | 1329 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1180 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2014 | 2618 | 0.080 |
Why?
|
| Young Adult | 7 | 2021 | 56430 | 0.080 |
Why?
|
| Operating Rooms | 1 | 2014 | 817 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 1770 | 0.080 |
Why?
|
| Spinal Cord | 1 | 2015 | 1809 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 39050 | 0.070 |
Why?
|
| Infant | 5 | 2014 | 35136 | 0.070 |
Why?
|
| Male | 17 | 2021 | 350118 | 0.060 |
Why?
|
| Humans | 22 | 2021 | 744343 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2017 | 4687 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2021 | 77449 | 0.060 |
Why?
|
| Female | 15 | 2017 | 380194 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2015 | 40561 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 3022 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2015 | 63114 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2015 | 2879 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13989 | 0.060 |
Why?
|
| Developing Countries | 1 | 2015 | 2815 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6895 | 0.050 |
Why?
|
| Recurrence | 1 | 2014 | 8340 | 0.050 |
Why?
|
| Pediatrics | 2 | 2014 | 3475 | 0.050 |
Why?
|
| Incidence | 3 | 2015 | 20947 | 0.050 |
Why?
|
| Risk | 1 | 2013 | 9687 | 0.050 |
Why?
|
| Survival Rate | 1 | 2013 | 12788 | 0.040 |
Why?
|
| Prognosis | 3 | 2015 | 29063 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 5137 | 0.040 |
Why?
|
| Internship and Residency | 2 | 2017 | 5788 | 0.040 |
Why?
|
| Time Factors | 3 | 2015 | 40075 | 0.040 |
Why?
|
| Cognition | 1 | 2015 | 6770 | 0.040 |
Why?
|
| Punctures | 1 | 2017 | 374 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2017 | 390 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 11124 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 804 | 0.030 |
Why?
|
| Middle Aged | 5 | 2017 | 213383 | 0.030 |
Why?
|
| Radiography | 2 | 2015 | 7023 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2017 | 512 | 0.030 |
Why?
|
| Education, Medical, Graduate | 2 | 2017 | 2291 | 0.030 |
Why?
|
| Hematocrit | 1 | 2015 | 636 | 0.030 |
Why?
|
| Jejunum | 1 | 2015 | 480 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 281 | 0.030 |
Why?
|
| Forearm | 1 | 2015 | 409 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 724 | 0.030 |
Why?
|
| United States | 3 | 2017 | 69872 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2013 | 224 | 0.030 |
Why?
|
| Infratentorial Neoplasms | 1 | 2013 | 94 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 501 | 0.030 |
Why?
|
| Trachea | 1 | 2017 | 1076 | 0.020 |
Why?
|
| Esophagus | 1 | 2017 | 1019 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 214055 | 0.020 |
Why?
|
| Length of Stay | 2 | 2015 | 6309 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 248 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2013 | 477 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2017 | 1210 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 603 | 0.020 |
Why?
|
| Intelligence | 1 | 2015 | 920 | 0.020 |
Why?
|
| Aged | 4 | 2017 | 163280 | 0.020 |
Why?
|
| Comprehension | 1 | 2015 | 610 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 35421 | 0.020 |
Why?
|
| Prostate | 1 | 2017 | 1774 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 975 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 975 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2015 | 1533 | 0.020 |
Why?
|
| Cerebellum | 1 | 2015 | 1488 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 57776 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 770 | 0.020 |
Why?
|
| Body Height | 1 | 2013 | 1577 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 6365 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2013 | 1357 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 20822 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1624 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2014 | 2530 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 3760 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3479 | 0.020 |
Why?
|
| Graft Survival | 1 | 2015 | 3737 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 8324 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 5952 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2759 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7785 | 0.010 |
Why?
|
| Cause of Death | 1 | 2013 | 3584 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8663 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 5391 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8642 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12245 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 6993 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 25043 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53288 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 12804 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 25625 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 13695 | 0.010 |
Why?
|
Concepts
(152)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(47)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_